Eupraxia Pharmaceuticals Inc. EPRX
8.01
(0.15)
(1.84%)
as of 25 Sep
- Market cap
- $537.8M
- P/E
- 0.0×
Follow EPRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
23.98 | 15.12 | 19.30 | 16.00 |
Net Debt/EBITDA |
13.03 | 5.00 | 8.64 | 7.35 | |
Debt/Assets |
0.10% | 0.09% | 1.24% | 1.20% | |
Debt/Equity |
0.00 | 0.00 | 0.01 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.64 | 0.56 | 0.77 | 0.87 | |
Capex/Depreciation |
(0.96) | (2.66) | (3.63) | (1.28) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.12) | (0.25) | (0.18) | (0.20) | |
Cash per Share |
2.41 | 2.02 | 2.45 | 2.02 | |
Shareholders Equity per Share |
2.40 | 2.01 | 2.40 | 1.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.40 | 2.01 | 2.40 | 1.96 | |
Free Cash Flow |
(4.57) | (9.92) | (10.47) | (13.27) | |
Working Capital |
87.59 | 79.47 | 134.76 | 128.25 | |
Capital Expenditures |
(0.06) | (0.19) | (0.33) | (0.17) | |
Net Current Asset Value |
87.49 | 79.39 | 132.96 | 126.57 | |
| Other line items | |||||
Quick Ratio |
23.38 | 14.43 | 18.95 | 15.71 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.12) | (0.24) | (0.18) | (0.20) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Average Receivables |
0.12 | 0.45 | 0.45 | 0.41 | |
Average Payables |
3.01 | 4.29 | 4.65 | 5.49 | |
Average Assets |
51.36 | 60.55 | 87.29 | 81.75 | |
Average Common Equity |
32.36 | 25.42 | 50.89 | 44.71 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates